Genprex (GNPX)
Market Price (1/27/2026): $2.48 | Market Cap: $37,721Sector: Health Care | Industry: Biotechnology
Genprex (GNPX)
Market Price (1/27/2026): $2.48Market Cap: $37,721Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -2985% | Weak multi-year price returns2Y Excs Rtn is -143%, 3Y Excs Rtn is -178% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Aging Population & Chronic Disease, and Precision Medicine. Themes include Gene Editing & Therapy, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -45375% | ||
| High stock price volatilityVol 12M is 4018% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 1266% | ||
| Key risksGNPX key risks include [1] substantial doubt about its ability to continue as a going concern due to severe cash constraints, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -2985% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Aging Population & Chronic Disease, and Precision Medicine. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -143%, 3Y Excs Rtn is -178% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -45375% |
| High stock price volatilityVol 12M is 4018% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 1266% |
| Key risksGNPX key risks include [1] substantial doubt about its ability to continue as a going concern due to severe cash constraints, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant Share Dilution from Capital Raises: Genprex undertook multiple registered direct offerings in October 2025, which led to substantial dilution for existing shareholders. For instance, an offering announced on October 28, 2025, to raise approximately $3.4 million upfront (with potential for an additional $6.6 million from warrants) at a purchase price of $9.00 per share, resulted in the stock plunging 20.1% on that day alone. A prior offering on October 23, 2025, sought to raise up to $8.2 million with shares priced at $11.21. The continuous need to raise capital through issuing new shares and warrants increased the share count and exerted significant downward pressure on the stock price.
2. Persistent Financial Concerns and Nasdaq Listing Compliance: The company has faced ongoing concerns regarding its ability to continue as a "going concern" and to meet Nasdaq's listing requirements. As of November 2025, while Genprex regained compliance with the minimum bid price, it received an extension until December 31, 2025, to meet the minimum stockholders' equity requirement, explicitly stating the need for additional capital raising to achieve compliance. Although compliance was eventually regained by January 7, 2026, the consistent struggle with financial stability and the threat of delisting highlighted underlying operational challenges.
Show more
Stock Movement Drivers
Fundamental Drivers
The -71.3% change in GNPX stock from 9/30/2025 to 1/26/2026 was primarily driven by a 3528.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 1262026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.47 | 2.43 | -71.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 0 | 3528.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 1/26/2026| Return | Correlation | |
|---|---|---|
| GNPX | -71.3% | |
| Market (SPY) | 4.0% | 0.1% |
| Sector (XLV) | 13.6% | 1.1% |
Fundamental Drivers
The -78.7% change in GNPX stock from 6/30/2025 to 1/26/2026 was primarily driven by a 1907.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 1262026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.39 | 2.43 | -78.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | 1907.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 1/26/2026| Return | Correlation | |
|---|---|---|
| GNPX | -78.7% | |
| Market (SPY) | 12.4% | -0.2% |
| Sector (XLV) | 17.8% | 1.3% |
Fundamental Drivers
The -94.3% change in GNPX stock from 12/31/2024 to 1/26/2026 was primarily driven by a -90.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312024 | 1262026 | Change |
|---|---|---|---|
| Stock Price ($) | 42.58 | 2.43 | -94.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -90.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2024 to 1/26/2026| Return | Correlation | |
|---|---|---|
| GNPX | -94.3% | |
| Market (SPY) | 19.2% | 0.3% |
| Sector (XLV) | 16.4% | 1.6% |
Fundamental Drivers
The -99.9% change in GNPX stock from 12/31/2022 to 1/26/2026 was primarily driven by a 57.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312022 | 1262026 | Change |
|---|---|---|---|
| Stock Price ($) | 2900.00 | 2.43 | -99.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | 57.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2022 to 1/26/2026| Return | Correlation | |
|---|---|---|
| GNPX | -99.9% | |
| Market (SPY) | 87.9% | 0.4% |
| Sector (XLV) | 21.8% | 1.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GNPX Return | -68% | 11% | -84% | -91% | -96% | 39% | -100% |
| Peers Return | -5% | -23% | -17% | 16% | -5% | 16% | -22% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% |
Monthly Win Rates [3] | |||||||
| GNPX Win Rate | 25% | 33% | 33% | 17% | 33% | 100% | |
| Peers Win Rate | 40% | 45% | 40% | 45% | 45% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| GNPX Max Drawdown | -71% | -24% | -87% | -96% | -99% | 0% | |
| Peers Max Drawdown | -39% | -50% | -43% | -34% | -50% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SRPT, CRSP, NTLA, BEAM, QURE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/26/2026 (YTD)
How Low Can It Go
| Event | GNPX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.5% | -25.4% |
| % Gain to Breakeven | 3867.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -74.6% | -33.9% |
| % Gain to Breakeven | 294.3% | 51.3% |
| Time to Breakeven | 326 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.5% | -19.8% |
| % Gain to Breakeven | 6511.2% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to SRPT, CRSP, NTLA, BEAM, QURE
In The Past
Genprex's stock fell -97.5% during the 2022 Inflation Shock from a high on 2/8/2021. A -97.5% loss requires a 3867.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Genprex (GNPX)
AI Analysis | Feedback
- Moderna for cancer gene therapy, but still clinical-stage.
- CRISPR Therapeutics for cancer gene therapy, but still clinical-stage.
AI Analysis | Feedback
Genprex (GNPX) Major Products:
- REQORSA® (quprelvir): An investigational immunogene therapy designed to deliver a tumor suppressor gene to cancer cells, currently in clinical trials for non-small cell lung cancer and other cancers.
- GPX-001 (Immunoproxâ„¢): An investigational gene therapy being developed to activate the immune system for the potential treatment of pancreatic cancer and melanoma.
- GPX-002: An investigational gene therapy designed to activate the immune system for the potential treatment of glioblastoma.
AI Analysis | Feedback
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing innovative therapies for cancer and other diseases. As a clinical-stage biotechnology company, Genprex does not currently have any commercialized products on the market.
Therefore, Genprex does not have major customers (either other companies or individuals) purchasing its products in the traditional commercial sense. Its operations are centered around research, development, and conducting clinical trials.
Instead of customers, Genprex's key relationships are with:
- Research institutions and academic medical centers that collaborate on preclinical studies and clinical trials.
- Strategic partners for the development and potential commercialization of its drug candidates (e.g., licensing agreements), rather than direct product sales.
- Patients participating in its ongoing clinical trials, who receive the investigational therapies as part of the research process, not as commercial purchasers.
The concept of "major customers" as described in the prompt does not apply to Genprex at its current stage of development.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here is the management team for Genprex (GNPX):Ryan M. Confer, President, Chief Executive Officer, and Chief Financial Officer
Ryan M. Confer was appointed President and Chief Executive Officer of Genprex in May 2024 and has served as Chief Financial Officer since September 2016. He previously held the roles of Chief Operating and Financial Officer from December 2013 to September 2016, and business manager from June 2011 to December 2013. Mr. Confer has been involved with Genprex since its inception in 2009 in various strategic, operations, and finance capacities, both as a consultant through his firm, Confer Capital, Inc., and as an employee. He possesses over a decade of entrepreneurial experience in planning, launching, developing, and growing emerging technology companies, serving in c-level and vice president roles since 2008. Notably, he was VP of Customer Experience and later VP of Strategy for KaiNexus, Inc., a company developing continuous improvement software. Prior to his entrepreneurial endeavors, Mr. Confer worked as a business development consultant for the University of Texas at Austin's IC2 Institute, evaluating the commercialization potential of nascent technologies. From 2006 to 2009, he served as a portfolio manager for a $500 million early-stage technology investment fund. He has experience structuring and negotiating deal terms for financing and licensing transactions.
Mark Berger, M.D., Chief Medical Officer
Dr. Mark Berger joined Genprex in September 2021 as Chief Medical Officer. He is a senior executive with 25 years of experience in biotech and pharmaceutical companies, focusing on the development of oncology therapeutics. Before Genprex, Dr. Berger was Chief Medical Officer for Actinium Pharmaceuticals, Inc., where he was responsible for clinical strategy and development of radioisotope-labeled antibodies for oncology therapy. He also served as Senior Vice President-Clinical Research at Kadmon Corporation, leading new drug development and oncology programs. Earlier in his career, he was Chief Medical Officer of Deciphera Pharmaceuticals and Vice President for Clinical Development at Gemin X Pharmaceuticals, which was acquired by Cephalon in March 2011 based on clinical trial results he led. Dr. Berger also held key positions at GlaxoSmithKline, managing the development of Tykerb (lapatinib), and at Wyeth Research, where he led the pivotal Phase 2 trial for Mylotarg. He is board certified in internal medicine, hematology, and medical oncology.
Thomas Gallagher, Esq., Senior Vice President of Intellectual Property & Licensing
Thomas C. Gallagher has more than 25 years of experience as an intellectual property attorney. Prior to joining Genprex, he was a Principal at the Fenagh Group, an IP and licensing consultancy. He also served as Senior Vice President of Intellectual Property and Licensing at Kadmon Corporation, LLC, and as in-house IP counsel at Neostem Inc. (now Caladrius Biosciences, Inc.). Earlier, he held several positions at ImClone Systems Incorporated, most recently as Vice President of Intellectual Property and Licensing. At ImClone, he was responsible for all aspects of intellectual property and played a key role in due diligence that led to a $2 billion strategic investment by Bristol Myers Squibb and the eventual sale of the company to Eli Lilly and Company for $6.5 billion.
David M. Schloss, Senior Vice President of Human Resources
David M. Schloss is the Senior Vice President of Human Resources at Genprex. No additional background information on founding or managing other companies, company sales, or private equity backing was readily available in the search results.
Suzanne Thornton-Jones, Ph.D., Senior Vice President, Regulatory Affairs and Quality
Suzanne Thornton-Jones, Ph.D., serves as the Senior Vice President, Regulatory Affairs and Quality at Genprex. No additional background information on founding or managing other companies, company sales, or private equity backing was readily available in the search results.
AI Analysis | Feedback
Genprex (GNPX) faces several critical risks to its business, primarily stemming from its status as a clinical-stage biotechnology company with no current product revenue. The most significant risks include:1. Liquidity and Ability to Continue as a Going Concern
Genprex faces substantial doubt about its ability to continue as a going concern due to its precarious financial health. As of its Q3 2025 filing, the company reported only $1.10 million in cash and cash equivalents against a significant cash burn of over $11.21 million in operating activities for the nine months ended September 30, 2025. This cash position is projected to be sufficient only into March 2026, necessitating continuous fundraising to sustain operations. The company has recurring losses, negative working capital, and is heavily reliant on equity financing.2. Clinical Trial Success and Regulatory Approval
The entire valuation and future of Genprex hinge on the successful outcomes of its clinical trials, particularly for its lead oncology candidate, REQORSA (GPX-001), in lung cancer (Acclaim-1 and Acclaim-3 trials). Clinical trial failures, delays in enrollment, or the inability of the drug to meet primary or secondary endpoints would lead to a catastrophic decline in stock price. The development and approval of novel gene therapy products are subject to extensive and evolving regulatory requirements, and any changes or increased scrutiny could delay or prevent product approval. Gene therapy trials in cancer also inherently carry low odds of success.3. Shareholder Dilution from Future Financing Activities
Given its significant cash burn and lack of revenue, Genprex relies heavily on issuing new equity to fund its research and development and ongoing operations. This reliance on equity financing has historically led to and is expected to continue causing substantial dilution for existing shareholders, putting pressure on the share price.AI Analysis | Feedback
nullAI Analysis | Feedback
Genprex (symbol: GNPX) is a clinical-stage gene therapy company with lead product candidates targeting cancer and diabetes. The addressable markets for their main products and services are as follows:
Reqorsa® Gene Therapy (quaratusugene ozeplasmid)
Reqorsa is Genprex's lead product candidate, currently being evaluated in clinical trials for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
- Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer therapeutics market was estimated at USD 20.2 billion in 2024 and is projected to reach USD 53.9 billion by 2034. The U.S. NSCLC market was valued at USD 8.2 billion in 2024.
- Small Cell Lung Cancer (SCLC): The global small cell lung cancer therapeutics market is estimated at USD 6.46 billion in 2024 and is predicted to surpass approximately USD 20.6 billion by 2034. The 7 Major Markets (7MM) for SCLC are expected to reach USD 23.0 billion by 2035.
GPX-002 (Diabetes Gene Therapy)
GPX-002 is Genprex's diabetes gene therapy approach, currently in preclinical development for Type 1 and Type 2 diabetes. The addressable market for diabetes treatment is substantial:
- United States Diabetes Market: Spending related to Type 1 diabetes in the U.S. is expected to reach USD 20.3 billion by 2029. Type 2 diabetes market sales in the U.S. are projected to climb to USD 57 billion by 2029.
- Global Diabetes Patient Population: Roughly 537 million people worldwide are living with diabetes, a figure expected to rise to 783 million by 2045.
NPRL2
NPRL2 is a tumor suppressor gene for which Genprex has filed intellectual property protection, with preclinical research in NSCLC cells. A specific addressable market size for NPRL2 as a distinct product is not identifiable in the provided information.
AI Analysis | Feedback
Genprex (GNPX), a clinical-stage gene therapy company, is currently not generating substantial revenue from product sales. Future revenue growth over the next 2-3 years will primarily be driven by the successful progression and commercialization of its pipeline candidates. Here are the expected drivers of future revenue growth for Genprex:- Successful Commercialization of Reqorsaâ„¢ for Lung Cancer: Genprex's lead oncology product candidate, Reqorsaâ„¢ (quaratusugene ozeplasmid), is in clinical development for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The Acclaim-3 trial for SCLC holds FDA Fast Track and Orphan Drug designations. The Phase 2a portion for NSCLC began dosing in January 2024 and is projected to complete enrollment by the end of 2025, with an interim data review anticipated in the first half of 2026. Achieving successful clinical trial outcomes and subsequent regulatory approvals will be crucial for the commercial launch of Reqorsaâ„¢ and its contribution to future revenue.
- Advancement and Commercialization of GPX-002 for Diabetes: Genprex is developing GPX-002, a preclinical gene therapy candidate aimed at reprogramming pancreatic cells to restore natural insulin production for both Type 1 and Type 2 diabetes. The successful advancement of this program through clinical trials and eventual commercialization could open up a significant new market and revenue stream for the company.
- Strategic Partnerships and Collaborations: Future revenue growth could be significantly enhanced through strategic partnerships with other pharmaceutical companies or research institutions. These collaborations can provide access to new technologies, additional funding, and specialized expertise, thereby accelerating the development and commercialization of Genprex's pipeline.
- Expansion of Reqorsaâ„¢ to Other Solid Tumors and Pipeline Enhancement: Genprex is actively engaged in preclinical research to explore the application of Reqorsaâ„¢ in combination with targeted therapies and immunotherapies for other solid tumors, such as ALK-positive NSCLC. Additionally, the company is investigating how other cancer-fighting genes, like NPRL2, can augment its portfolio utilizing the ONCOPREX Delivery System. Broadening the therapeutic applications of its lead candidate and core technology to a wider range of cancers would expand Genprex's total addressable market and potential for future revenue generation.
AI Analysis | Feedback
Share Issuance
- Genprex announced a registered direct offering of up to $10.0 million on October 28, 2025.
- On October 23, 2025, the company announced another registered direct offering of up to $8.2 million.
- In March 2024, Genprex completed a registered direct offering, generating gross proceeds of approximately $6.5 million from the sale of 1,542,112 shares of common stock (or prefunded warrants) and accompanying warrants.
Inbound Investments
- Genprex has received capital through several registered direct offerings, including approximately $6.5 million in March 2024, up to $8.2 million in October 2025, and up to $10.0 million in October 2025.
Capital Expenditures
- Genprex primarily relies on third-party contract development and manufacturing organizations (CDMOs) for the production of its product candidates.
- The company has transferred manufacturing processes from MD Anderson to CDMOs and scaled up clinical production for its Acclaim-1 and Acclaim-3 clinical trials.
- Publicly available financial data often reports "n/a" or a dash for capital expenditures, suggesting these are not significant line items for the company.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 24.04 |
| Mkt Cap | 1.9 |
| Rev LTM | 45 |
| Op Inc LTM | -320 |
| FCF LTM | -340 |
| FCF 3Y Avg | -284 |
| CFO LTM | -274 |
| CFO 3Y Avg | -266 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -44.9% |
| Rev Chg 3Y Avg | 40.6% |
| Rev Chg Q | 18.4% |
| QoQ Delta Rev Chg LTM | 0.0% |
| Op Mgn LTM | -837.1% |
| Op Mgn 3Y Avg | -658.9% |
| QoQ Delta Op Mgn LTM | -3.5% |
| CFO/Rev LTM | -713.8% |
| CFO/Rev 3Y Avg | -374.0% |
| FCF/Rev LTM | -717.3% |
| FCF/Rev 3Y Avg | -402.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.9 |
| P/S | 57.0 |
| P/EBIT | -7.7 |
| P/E | -7.0 |
| P/CFO | -9.4 |
| Total Yield | -14.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -20.2% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.8% |
| 3M Rtn | -11.3% |
| 6M Rtn | 27.5% |
| 12M Rtn | 22.5% |
| 3Y Rtn | -49.1% |
| 1M Excs Rtn | 7.4% |
| 3M Excs Rtn | -35.5% |
| 6M Excs Rtn | 13.8% |
| 12M Excs Rtn | 7.1% |
| 3Y Excs Rtn | -120.8% |
Price Behavior
| Market Price | $2.43 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/29/2018 | |
| Distance from 52W High | -93.1% | |
| 50 Days | 200 Days | |
| DMA Price | $2.74 | $9.20 |
| DMA Trend | down | down |
| Distance from DMA | -11.5% | -73.6% |
| 3M | 1YR | |
| Volatility | 140.9% | 4,034.5% |
| Downside Capture | 691.65 | 460.69 |
| Upside Capture | -78.06 | 131.53 |
| Correlation (SPY) | 22.6% | 0.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.39 | 3.32 | 1.23 | -1.17 | 0.61 | 0.63 |
| Up Beta | -16.12 | -6.07 | -10.76 | -4.50 | 0.23 | 0.64 |
| Down Beta | 3.34 | 6.55 | 248.19 | 139.88 | 31.44 | 18.65 |
| Up Capture | -120% | -80% | 183% | 138% | 62% | -6% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 5 | 11 | 18 | 41 | 97 | 296 |
| Down Capture | 817% | 587% | 523% | 378% | 171% | 112% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 16 | 29 | 45 | 84 | 148 | 439 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GNPX | |
|---|---|---|---|---|
| GNPX | -93.2% | 4,018.5% | 0.96 | - |
| Sector ETF (XLV) | 11.2% | 17.3% | 0.46 | 1.7% |
| Equity (SPY) | 14.7% | 19.3% | 0.58 | 0.4% |
| Gold (GLD) | 84.5% | 20.5% | 2.90 | -32.2% |
| Commodities (DBC) | 9.2% | 15.4% | 0.37 | -6.6% |
| Real Estate (VNQ) | 4.0% | 16.5% | 0.06 | -0.9% |
| Bitcoin (BTCUSD) | -14.0% | 39.8% | -0.29 | -4.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GNPX | |
|---|---|---|---|---|
| GNPX | -80.1% | 1,805.7% | 0.42 | - |
| Sector ETF (XLV) | 7.7% | 14.5% | 0.35 | 1.2% |
| Equity (SPY) | 14.3% | 17.1% | 0.67 | 1.0% |
| Gold (GLD) | 22.1% | 15.7% | 1.14 | -18.0% |
| Commodities (DBC) | 12.0% | 18.7% | 0.52 | -2.1% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.19 | 0.0% |
| Bitcoin (BTCUSD) | 20.0% | 57.9% | 0.55 | -0.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GNPX | |
|---|---|---|---|---|
| GNPX | -56.2% | 1,450.9% | 0.37 | - |
| Sector ETF (XLV) | 10.8% | 16.6% | 0.54 | 1.7% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 1.7% |
| Gold (GLD) | 16.2% | 14.9% | 0.90 | -14.3% |
| Commodities (DBC) | 8.7% | 17.6% | 0.41 | -1.3% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 1.2% |
| Bitcoin (BTCUSD) | 73.4% | 66.6% | 1.12 | -0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/21/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.